Opdyta — Nivolumab
Nivolumab is a PD-1 immune checkpoint inhibitor — it works by blocking a signal tumors use to hide from the immune system, allowing the body's own defenses to attack cancer cells.
- Approved indications: Melanoma, NSCLC, malignant pleural mesothelioma, renal cell carcinoma, classical Hodgkin lymphoma, head & neck squamous cell carcinoma, urothelial carcinoma, colorectal cancer, hepatocellular carcinoma, esophageal/gastric cancers
- Common combination: Often paired with Ipilimumab for dual checkpoint blockade in first-line metastatic disease
- Strongest export demand: Lung and liver cancer treatment, particularly Africa and LATAM markets
Key Product Facts
100 mg
Strength
1 Vial (S) Of 10 ml
Pack Size
Nivolumab
Active Ingredient
Oncology
Category
Enquire Now for Pricing
Price
Nivolumab is a PD-1 immune checkpoint inhibitor — it works by blocking a signal tumors use to hide from the immune system, allowing the body's own defenses to attack cancer cells.
- Approved indications: Melanoma, NSCLC, malignant pleural mesothelioma, renal cell carcinoma, classical Hodgkin lymphoma, head & neck squamous cell carcinoma, urothelial carcinoma, colorectal cancer, hepatocellular carcinoma, esophageal/gastric cancers
- Common combination: Often paired with Ipilimumab for dual checkpoint blockade in first-line metastatic disease
- Strongest export demand: Lung and liver cancer treatment, particularly Africa and LATAM markets
- Administration: Hospital-only, IV infusion under oncologist supervision
- Order confirmation requires: Valid prescription + import permit (where applicable)
- Key risk category: Immune-related adverse events — pneumonitis, colitis, hepatitis, endocrinopathies
- Monitoring required: Baseline and ongoing lab work throughout treatment
- High-caution populations: Autoimmune disease, transplant recipients, pregnancy (Category D)
| Document |
Included |
| Certificate of Analysis (COA) |
? Standard |
| Certificate of Origin (COO) |
? Standard |
| Free Sale Certificate (FSC) |
? Standard |
| Commercial Invoice & Packing List |
? Standard |
| MSDS |
Where required |
| WHO-GMP / USFDA / MHRA / TGA / ANVISA / NAFDAC |
On request, matched to destination |
Stock status: Both strengths in stock | Quote turnaround: 24 hours
- Logistics: GDP-compliant cold chain, air and sea freight
- Validated temperature ranges: 2–8°C, 15–25°C, -20°C
- Active corridors: Peru, Chile, Brazil, Colombia, Argentina (LATAM); Nigeria, Kenya, South Africa, Ghana, Ethiopia (Africa)
- On-inquiry markets: Middle East, Southeast Asia, Central Asia, Eastern Europe
What is Nivolumab used for?
An immunotherapy drug for melanoma, lung cancer, kidney cancer, and other advanced cancers.
Get Nivolumab price from a GMP-compliant Indian supplier — how?
Send strength, quantity, and destination for a verified quote within 24 hours.
Can hospitals import if unregistered locally?
Yes, via named-patient/compassionate-use import — we guide the process.
Do you supply in bulk to distributors?
Yes, regularly, to importers, distributors, and hospital procurement teams.
What documents come with export shipments?
COA, COO, FSC, invoice, packing list, MSDS — plus country-specific certification on request.
Is cold chain guaranteed?
Yes, GDP-compliant temperature-controlled logistics for every shipment.
